Taher Modarressi, MD
@tmodarressi
Followers
2K
Following
4K
Media
385
Statuses
2K
Cardiometabolic medicine. Endocrinology, lipidology, obesity medicine. Via @PennMedicine and @MGHMedicine.
New Jersey, USA
Joined April 2020
RT @CMichaelGibson: A large, cluster-randomized controlled trial convincingly demonstrated that better blood pressure, below 130/80 mm Hg,….
statnews.com
Keeping blood pressure below 120/80 lowers risk of dementia, as well as heart and kidney disease, new guidelines say.
0
27
0
RT @scottisaacsmd: Breaking! The FDA has approved Wegovy #semaglutide to treat #MASH in adults with moderate-to-advanced fibrosis. https://….
0
115
0
Across so many disease states and disciplines, combo therapy is a winning strategy!.
Original Article: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (CONFIDENCE trial) . Editorial: Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes — A Promising Prelude . #Endocrinology
1
3
16
RT @khurramn1: Couldn’t agree more.#KeepItSimple. Whom to treat: forgot #RiskScores rather think Imaging #SeeDiseaseTreatDisease #CAC. What….
0
6
0
RT @Lpa_Doc: We have a new paper in press with our Hopkins colleagues led by Thorsten Leucker's group. More evidence that OxPL-apoB and OxP….
0
15
0
Great article, worth a read!.
🚨Now on PubMed!.Our latest paper explores LDL-C targets informed by CAC scoring, expanding on Fig 6 from the 2022 ACC-ECDP. We cover:.🧠 When to get a CAC in the PREVENT era.💊 Statin & non-statin therapy guided by CAC.📉 Smarter risk-based LDL goals.
0
0
2
RT @mvaduganathan: Wow, the game has changed! #SURPASSCVOT meets its primary & secondary endpoints in first *head-to-head* CV outcomes tria….
0
68
0
RT @AnandVaidya17: Subclinical Primary Aldosteronism — any aldosterone produced when renin is low, even in normotensive people -- associate….
0
5
0
I thought these things were supposed to get smoother and easier over time! In particular a 2.6 fold increase in cost ascribed to "current conditions in the market" seems unusual.
0
0
0
Two unfortunate changes this week that directly impact our patients: (1) Novo's patient assistance program will require manual faxed paper refills each time and (2) Ambry is increasing cash-pay genetic testing from $250 to $650, making it largely inaccessible for most of our pts.
1
0
6
RT @AnandVaidya17: New Primary Aldosteronism Guidelines - simpler, streamlined, and hopefully more pragmatic. http….
0
103
0
RT @MWilkinsonMD: ➡️In @LipidJournal: real-world data, early experience with inclisiran @UCSDHealth @UCSDCardiology . Congrats @DMazdeyasna….
0
7
0
RT @Drlipid: BIG NEWS in the obicetrapib story - Patients had significant reductions in the biomarker p-tau217 comp….
fiercebiotech.com
NewAmsterdam Pharma’s push to show a cholesterol drug can prevent Alzheimer’s disease has passed another test. | NewAmsterdam Pharma’s push to show a cholesterol drug can prevent Alzheimer’s disease...
0
18
0
RT @hsbhatia: Our new study on the AHA PREVENT Equations and Lp(a) is out now @JAMACardio @AlexRazavi @JSpitz_MD @jaideeppatelmd @DrMichael….
0
28
0
Great framework for clinically differentiating FCS and MCS by @Dr_Zahid_Ahmad at #NLASessions.
1
4
18
RT @MichaelAlbertMD: 🧪 New Phase 2 Trial: High-Dose Semaglutide (up to 16 mg/week).---.Can more sema drive more results in type 2 diabetes….
0
15
0
RT @KevinH_PhD: Really enjoyed Max Petersen’s talk at #NLASessions on the topic of hypothetical mechanisms of increased LDL cholesterol an….
0
26
0
A particularly meaningful moment to see my great teacher and mentor, and the person who first sparked my interest in lipids, @dan_soffer receive the @nationallipid Clinician Educator Award at #NLASessions.
0
6
43
Phenomenally rich talk on FH by @DrSafarova at #NLASessions highlighting the phenotypic heterogeneity of LDLr pathogenic variants, updated prevalence data and range of yield with genetic testing.
0
6
20
And perhaps the most intriguing data presented by @KevinH_PhD at #NLASessions: Interim analysis from a fascinating trial suggests UPFs may not inherently drive weight gain; instead, it’s energy density and hyperpalatability of the UPFs that is associated with ad lib energy intake
6
33
111